author-photo

Mark W. Russo

GlaxoSmithKline

23

Papers

481

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Abstract CT328: Exploratory genetic analysis of tumors from a phase I/II dose escalation study of GSK2636771 in patients (pts) with PTEN deficient advanced tumors

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (22)
Evaluation of pro-apoptotic BIM gene loss of function on lapatinib efficacy in patients with metastatic breast cancer (MBC) and in HER2-amplified cell lines.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Integration of modeling and simulation to support changes to ondansetron dosing following a randomized, double‐blind, placebo‐, and active‐controlled thorough QT study

2014 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (22)
Randomized Trial of Lapatinib Versus Placebo Added to Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancer

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (115)
Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

2012 Supportive Care in Cancer
Show All
- Source
- Cite
- Save
Citations (25)
Phase III study of single-dose casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting.

2011 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy.

2010 Supportive Care in Cancer
Show All
- Source
- Cite
- Save
Citations (9)
3086 Efficacy of casopitant, a novel NK-1 receptor antagonist, for antiemesis over repeated cycles of moderately emetogenic therapy

2009 Ejc Supplements
Show All
- Source
- Cite
- Save
Citations (0)